{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SAFFRON","nct_id":"NCT05261399","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=saffron-nct05261399. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SAFFRON","arms":[{"description":"Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"},{"description":"300 mg savolitinib BID plus 80 mg osimertinib QD","label":"Savolitinib + Osimertinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-23","type":"ESTIMATED"},"conditions":["Carcinoma","Non-Small-Cell Lung"],"enrollment":{"count":341,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Savolitinib","otherNames":["AZD6094, HMPL-504, volitinib"],"type":"DRUG"},{"name":"Osimertinib","otherNames":["AZD9291, Tagrisso"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["NAP"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["NAP"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["NAP"],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-07-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.","timeFrame":"Approximately 36.5 months post first subject randomized"}],"references":[],"start_date":{"date":"2022-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","url":"https://clinicaltrials.gov/study/NCT05261399"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/saffron-nct05261399"}